Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REDDSTAR (ORBCEL-M) for Non-healing Neuroischaemic Diabetic Foot Wounds
NCT03509870Phase 1Terminated
- Sponsor
- Steno Diabetes Center Copenhagen
- Start
- Jun 2018
- Primary completion
- Apr 2020
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of ORBCEL-M in diabetic foot ulcer (DFU), sponsored by Steno Diabetes Center Copenhagen. Started Jun 2018; status: terminated.
02
Drugs
ORBCEL-M
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on NCT03509870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03509870.